Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yeejin Jeon
Institution:
Qurient (South Korea)
Observed institution:
Qurient (South Korea)
ORCID:
0000-0002-8413-4406
Observed ORCID:
0000-0002-8413-4406
OpenAlex ID:
A5066670477
Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects
2021
·
Jeongjun Kim
, Jinho Choi
, et al.
·
Antimicrobial Agents and Chemotherapy
·
39
A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment
2022
·
Yeejin Jeon
, Hwankyu Kang
, et al.
·
Cancers
·
22
PDF
Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial
2022
·
Jeongjun Kim
, Jinho Choi
, et al.
·
Antimicrobial Agents and Chemotherapy
·
16
An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity
2024
·
DongHoon Yu
, Sabrina Wagner
, et al.
·
Pharmaceutics
·
13
PDF
Abstract 1953: Q901, a selective CDK7 inhibitor, a potential new strategy for primary and CDK4/6 inhibitor resistant ER-positive breast cancer
2021
·
Donghoon Yu
, Yeejin Jeon
, et al.
·
Cancer Research
·
4
Abstract 4855: Development of highly selective CDK7 inhibitor Q901 for solid tumors
2020
·
Donghoon Yu
, Yeejin Jeon
, et al.
·
Cancer Research
·
4
Abstract 4139: Q702, selective Axl, Mer and CSF1R triple kinase inhibitor with dual potentials leading to tumor regression: Immuno-oncology therapy and targeted cancer therapy
2019
·
Yeong-In Yang
, Hwankyu Kang
, et al.
·
Cancer Research
·
4
Abstract 3313: Discovery of a potent, selective, and orally available small molecule for disruption of the SOS1-RAS interaction
2024
·
Dong Hyuk Ki
, Hana Yu
, et al.
·
Cancer Research
·
2
Abstract 2574: Q901; a highly selective covalent cdk7 inhibitor inducing substantial anti-tumor effect in a broad spectrum of solid tumor lineages
2022
·
Donghoon Yu
, Yeejin Jeon
, et al.
·
Cancer Research
·
2
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
2021
·
Angela Tatiana Alistar
, Anthony B. El-Khoueiry
, et al.
·
Journal of Clinical Oncology
·
2
Abstract 4974: Q702, selective Axl/Mer/CSF1R triple kinase inhibitor enhance the activity of immune checkpoint inhibitor by alteration of immunosuppressive tumor microenvironment
2020
·
Yeong-In Yang
, Hwankyu Kang
, et al.
·
Cancer Research
·
2
Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition
2026
·
Hyerim Jung
, Yoonji Lee
, et al.
·
Science Advances
·
1
Abstract 657: Discovery of a novel brain penetrant SHP2 allosteric inhibitor with anti-tumor effects
2024
·
Miyeon Kim
, Dongsu Kim
, et al.
·
Cancer Research
·
1
Abstract 4139: Q702, selective Axl, Mer and CSF1R triple kinase inhibitor with dual potentials leading to tumor regression: Immuno-oncology therapy and targeted cancer therapy
2019
·
Yeong-In Yang
, Hwankyu Kang
, et al.
·
Immunology
·
1
Abstract 4032: Discovery of a potent, selective, and orally available SHP2 inhibitor that can penetrate blood-brain barrier
2023
·
Miyeon Kim
, Dongsu Kim
, et al.
·
Cancer Research
Abstract 4016: Discovery of a small-molecule EGFR inhibitor that can potently target various EGFR mutants, including C797S mutant, in vitro and in vivo
2023
·
Yeejin Jeon
, Kiram Lee
, et al.
·
Cancer Research
Abstract 5977: Evaluation of the potential combination regimens for q901, a clinical stage selective cdk7 inhibitor, as a DNA damage repair inhibitor
2023
·
Donghoon Yu
, Yeejin Jeon
, et al.
·
Cancer Research
Abstract 416: A novel non-covalent and rapidly reversible proteasome inhibitor for multiple myeloma and various solid cancers
2022
·
Won-Gyun Ahn
, Yeejin Jeon
, et al.
·
Cancer Research
Abstract B162: Highly selective, orally available CDK7 inhibitor for cancer therapy
2018
·
Yeejin Jeon
, Donghoon Yu
, et al.
·
Molecular Cancer Therapeutics
Show more works
View as search
Works count:
19
Citation count:
113
H-index:
4
I10-index:
4
Year
Topic
Type
